Pseudoprogression as an adverse event of glioblastoma therapy

We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Balaña, Carmen, Capellades, Jaume, Pineda, Estela, Estival, Anna, Puig, Josep, Domenech, Sira, Verger, Eugenia, Pujol, Teresa, Martinez‐García, Maria, Oleaga, Laura, Velarde, JoseMaria, Mesia, Carlos, Fuentes, Rafael, Marruecos, Jordi, Del Barco, Sonia, Villà, Salvador, Carrato, Cristina, Gallego, Oscar, Gil‐Gil, Miguel, Craven‐Bartle, Jordi, Alameda, Francesc
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5727237/
https://ncbi.nlm.nih.gov/pubmed/29105360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1242
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars